ACR-368 - In OncoSignature-positive endometrial cancer subjects, the Objective Response Rate (ORR) with ACR-368 single agent is 39% (n=31)[31] - In subjects with ≤ 2 prior lines of therapy, the ORR in BM+ subjects is 44% (n=25) and in BM- subjects is 26% (n=35) with ACR-368 single agent and ACR-368 + ULDG combo, respectively[34] - In BM+ subjects with ≤ 2 prior lines, the ORR in serous carcinosarcoma is 67% (n=12)[37] - In biomarker-unselected subjects with ≤ 2 prior lines, the ORR in serous subjects is 52% (n=23) and in non-serous subjects is 22% (n=37)[40] - In serous subjects with ≤ 2 prior lines, the Disease Control Rate (DCR) is 92% and Clinical Benefit Rate (CBR) at 16 weeks is 83% in Arm 1 (BM+), while in Arm 2 (BM-) the DCR is 55% and CBR at 16 weeks is 45%[43] - Serous endometrial cancer accounts for approximately 40% of all endometrial cancer deaths, equating to roughly 20,000 deaths per year in the US and EU[46, 52] ACR-2316 - In the Phase 1 dose escalation study, clinical activity was observed at dose level 120 mg and above, with tumor shrinkage in 9 out of 20 evaluable patients[74] - A total of 33 patients were dosed across two weekly dosing schedules in the ongoing Phase 1 monotherapy dose-escalation study[68, 74] - In the Phase 1 study, 79% of the subjects were White, 9% were Black/African American, 3% were Asian, 3% were Native Hawaiian/Pacific Islander, and 6% were Unknown/Other[69] Financials - As of December 31, 2025, Acrivon has approximately $119 million in cash and investments, projecting a runway into Q2 2027[96]

Company Overview - Acuity Brands Lighting (ABL) net sales for Q1'26 were $669 million[23], while Acuity Intelligent Spaces (AIS) net sales for Q1'26 were $948 million[28] - ABL Adjusted Operating Profit Margin for Q1'26 was 18.5%[23], and AIS Adjusted Operating Profit Margin for Q1'26 was 21.7%[28] Financial Performance - The company's net sales have grown from $1.7 billion in FY09 to $4.5 billion in LTM Q1'26[34] - Adjusted Operating Profit has increased from $186 million in FY10 to $806 million in LTM Q1'26[35] - Adjusted Diluted Earnings Per Share have risen from $2.42 in FY10 to $18.73 in LTM Q1'26[37] - Free Cash Flow generation has increased from $139 million in FY10 to $534 million in LTM Q1'26[38] Capital Allocation - The company has repurchased approximately $1.5 billion of its shares outstanding since the beginning of the 4th quarter of 2020, representing about 25% of the then-outstanding shares[31] Non-GAAP Measures - The company uses non-GAAP financial measures such as adjusted operating profit, adjusted net income, and free cash flow to enhance the understanding of its financial performance and prospects[4] - These non-GAAP measures are used for internal reviews of performance, baseline comparative operational analysis, and decision-making[5]

Financial Performance - Neogen's core revenue increased by 2.9% year-over-year[9] - Adjusted EBITDA margins improved sequentially by 470 bps to 21.7%[9] - Q2 FY26 revenue reached $224.7 million[19] compared to $209.2 million in Q1 FY26 and $231.3 million in Q2 FY25[19] - Adjusted EBITDA for Q2 FY26 was $48.7 million with a margin of 21.7%[20], compared to $35.5 million with a margin of 17.0% in Q1 FY26 and $51.4 million with a margin of 22.2% in Q2 FY25[20] - Adjusted Net Income for Q2 FY26 was $22.6 million[21], or $0.10 per share[21], compared to $9.4 million[21], or $0.04 per share in Q1 FY26[21], and $24.4 million[21], or $0.11 per share in Q2 FY25[21] Segment Performance - Food Safety core revenue grew by 4.1%[23] - Animal Safety core revenue grew by 0.1%[23] Balance Sheet and Capital Allocation - Net debt is $655 million[26] - Debt is 68% fixed[26] - Q2 Free Cash Flow improved by $21 million compared to Q1[28] FY2026 Outlook - Total revenue is projected to be between $845 million and $855 million[32] - Adjusted EBITDA is expected to be approximately $175 million[32] - Capital expenditures are estimated at around $50 million[32] - The effective tax rate is projected at 21%[32]

Company Overview - VolitionRx is focused on saving lives and improving outcomes through low-cost testing in cancer, sepsis, and veterinary applications[4, 5] - The company operates with a low capex, low opex business model, emphasizing commercial partnerships and out-licensing[21] - VolitionRx leverages its IP Powerhouse with 56 patent families and a team with hundreds of years of experience[5] Commercialization and Licensing - The company received $10 million upfront and $13 million in milestone payments from an exclusive Element i+ in-house analyzer licensing partnership[29] - In 2024, Volition sold over 120,000 Nu.Q® Vet Cancer Tests & Components[40] - The company is targeting multiple licensing deals in the human space in 2026, focusing on upfront, milestone, and recurring revenue[25] Products and Market - Nu.Q® Vet is available in the United States, Europe, and Asia, detecting 76% of systemic cancers at 97% specificity[38, 40] - The company estimates a $170 million non-regulated animal testing licensing market, a $4 billion lab-developed screening/management market, and a >$3 billion ICU/ED CE Mark/FDA NETosis sales & licensing market[36] - Lung cancer screening and disease management with Nu.Q® is forecasted to reach over 3 million tests by 2035[63]

2025 Recaps - FF signed an MOU with RAK Digital Assets Oasis to collaborate on AI, Web3, and Embodied Intelligence[23] - FX Super One debuted in LA on July 17, 2025, securing over 11,000 non-binding B2B pre-orders[25] - FF launched Faraday X (FX) in late 2024, with U S homologation and road testing for FX Super One beginning in early 2025[25,27] FX Super One Roadmap - The first U S pre-production FX Super One rolled off the line in Hanford, California on Dec 21st[33] - Initial deliveries of FX Super One to FX Par co-creation partners are planned for Q2 2026[43] - Expanded deliveries to industry leaders and B2B partners are slated for Q3 2026[47] - Full-scale U S delivery of FX Super One is targeted for Q4 2026 / Q1 2027[49] Five-Year Business Plan - The company's five-year cumulative production and sales target is 400,000–500,000 vehicles[82,125] - The company aims to achieve positive EBITDA within three years, targeting a contribution margin rate of over 20%[82,126] - Production and sales targets for 2026 are 4,900 units, increasing to 33,000 in 2027, 130,000 in 2028, 250,000 in 2029, and reaching 400,000-500,000 in 2030[77,82]

Company Overview - Acuity Brands Lighting (ABL) net sales were $3612 million in FY25 and $3621 million in LTM Q1'26[46] - Acuity Intelligent Spaces (AIS) net sales were $764 million in FY25 and $948 million in LTM Q1'26[47] Financial Performance - The company's net sales have grown from $17 billion in FY09 to $4538 billion in LTM Q1'26[34, 42] - Adjusted operating profit increased from $196 million in FY09 to $806 million in LTM Q1'26[35, 42] - Adjusted diluted earnings per share increased from $274 in FY09 to $1873 in LTM Q1'26[37] - Free cash flow increased from $72 million in FY09 to $534 million in LTM Q1'26[38, 44] Capital Allocation - The company has repurchased approximately $15 billion of its shares outstanding from the beginning of the 4th quarter of 2020, representing approximately 25% of the then-outstanding shares[31] ABL Performance - ABL Adjusted Operating Profit was $662 million in FY25 and $669 million in LTM Q1'26[23, 46] - ABL Adjusted Operating Profit Margin was 183% in FY25 and 185% in LTM Q1'26[23, 46] AIS Performance - AIS Adjusted Operating Profit was $164 million in FY25 and $206 million in LTM Q1'26[28, 47] - AIS Adjusted Operating Profit Margin was 215% in FY25 and 217% in LTM Q1'26[28, 47]

Greatness Starts Here We transform organizations by building exceptional leaders, teams, and cultures that get results. INVESTOR UPDATE First Quarter Fiscal 2026 This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward -looking statements are based upon management's current expectations and are subject to various risks and uncertainties including, but not limited to : The ability of the Company to grow revenues; The acceptanc ...

BlackBerry Overview - BlackBerry has 3 divisions: QNX, Secure Communications, and Licensing[12] - The company's 2025 revenue was approximately $532 million[12] - BlackBerry has significantly enhanced its cash flow profile, with operating cash flow increasing from -$262 million in FY23 to $17 million in FY25[12] - BlackBerry's QNX is on a path to a "Rule of 40" division[50] QNX Performance and Market - QNX is a leader in automotive and other embedded systems[15] - QNX is experiencing double-digit revenue growth[15] - QNX's serviceable addressable market (SAM) is projected to grow from $1.8 billion in CY2024 to $2.9 billion in CY2028, with a core CAGR of approximately 8-14%[18] - QNX total CAGR is projected to be ~34% from '24 to '28[18] - QNX royalty backlog was up to $865 million in Q4 FY'25, compared to $460 million in Q4 FY'22[50] Strategic Initiatives - BlackBerry is focused on solution innovation, including product and technology bundles and flexible pricing strategies[35] - BlackBerry is strategically collaborating with Vector to transform the traditional automotive value chain[36] - BlackBerry is expanding QNX access to more developers through the QNX Everywhere program, with over 12,000 SDP 8.0 licenses deployed for non-commercial use[48]

Financial Performance and Growth - The company's Utilities segment revenue reached $2.658 billion in TTM Q3 2025[9], while the Energy segment revenue was $4.931 billion in TTM Q3 2025[12, 19] - The company's backlog for Utilities was $6.593 billion in Q3 2025[15], and for Energy was $4.470 billion in Q3 2025[20] - The company targets a gross profit growth of 9% to 12%[38, 84] - The company projects full year 2025 Adjusted EBITDA to be between $510 million and $530 million[88, 98] - The company anticipates full year 2025 Adjusted EPS to be in the range of $5.35 to $5.55 per diluted share[88, 96] Strategic Focus and Market Positioning - The company is focused on high-growth markets like Renewables and Power Delivery[38, 41] - The company aims to grow solar revenue from $1.3 billion in 2023 to $2.9 billion in TTM Q3 2025[63] - The company is targeting an operating cash flow margin of 4% to 5% by 2026[84] - The company is aiming for a Net Debt / Adjusted EBITDA target of 1.5x[68, 84] Contract and Customer Base - Reimbursable contracts account for 51% of revenue, while fixed-price contracts account for 49% in TTM Q3 2025[25] - The company derives 41% of its revenue from its top 10 customers[33]

Financial Performance - Q3 FY26 - Net sales increased by 2.1% year-over-year (YoY) to $348.6 million[12, 13] - Adjusted EBITDA increased by 0.7% YoY to $46.1 million[12, 13] - Adjusted EBITDA margin decreased by 20 basis points (bps) YoY to 13.2%[12, 13] - Adjusted diluted EPS decreased by 14.3% YoY to $1.02[12, 13] Segment Performance - Q3 FY26 - Architectural Metals net sales decreased by 9.9% YoY to $124.4 million[23] - Architectural Services net sales increased by 0.2% YoY to $105.2 million[23] - Architectural Glass net sales increased by 0.9% YoY to $70.9 million[23] - Performance Surfaces net sales increased by 59.6% YoY to $53.0 million[23] Cash Flow and Debt - Free cash flow for the nine months ended November 29, 2025, was $48.3 million, compared to $70.4 million for the same period in the previous year[27] - Total debt as of November 29, 2025, was $255.0 million, down from $285.0 million as of March 1, 2025[27] FY26 Outlook - The company updated its full-year FY26 net sales outlook to approximately $1.39 billion (previously $1.39 billion - $1.42 billion)[41] - The company updated its full-year FY26 adjusted diluted EPS outlook to $3.40 - $3.50 (previously $3.60 - $3.90)[41] - Tariffs are estimated to reduce full-year adjusted diluted EPS by $0.30[45]